Merck & Co., Inc.
- Last sale
- Nov 12, 2026 · -0.17%
- Market cap
- $362.27B
- 2.47B shares
- Filings
- 1,075
Q3 2026+1.3% FY25 yoy
Q3 2026+6.6% FY25 yoy
—
—
—Q3 2026derived−31.7% FY25 yoy
Q3 2026+8.0% FY25 yoy
Q3 2026+10.0% FY25 yoy
- $362.27B
- 147.7×
- 5.4×
- 8.1×
- 4.07%
- 2.31%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $65,011,000,000 | reported | |
| FY 2024 | 2024-12-31 | $64,168,000,000 | reported | |
| FY 2023 | 2023-12-31 | $60,115,000,000 | reported | |
| FY 2022 | 2022-12-31 | $59,283,000,000 | reported | |
| FY 2021 | 2021-12-31 | $48,704,000,000 | reported | |
| FY 2020 | 2020-12-31 | $41,518,000,000 revised | reported | |
| FY 2019 | 2019-12-31 | $39,121,000,000 revised | reported | |
| FY 2018 | 2018-12-31 | $42,294,000,000 | reported | |
| FY 2017 | 2017-12-31 | $40,122,000,000 | reported | |
| FY 2016 | 2016-12-31 | $39,807,000,000 | reported | |
| FY 2015 | 2015-12-31 | $39,498,000,000 | reported | |
| FY 2014 | 2014-12-31 | $42,237,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $8.18B | $5.08B | $13.26B | $3.28 | 2.47B sh | −2.1% | 107.3% |
| FY2024 | $7.84B | $1.31B | $9.15B | $3.12 | 2.53B sh | −0.3% | 50.5% |
| FY2023 | $7.45B | $1.35B | $8.79B | $2.96 | 2.53B sh | −0.2% | 96.2% |
| FY2022 | $7.01B | $0.00 | $7.01B | $2.80 | 2.54B sh | +0.4% | 47.7% |
| FY2021 | $6.61B | $840.00M | $7.45B | $2.64 | 2.53B sh | −0.1% | 85.9% |
Segments
LineFY2025ShareChange
Pharmaceutical segment$58.14B89%+1.3%
Animal Health$6.35B9.8%+8.1%
Other segments———
Total$65.01B
Pharmaceutical preparations
Merck & Co., Inc. is the 3rd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JNJJohnson & Johnson$94.2B6.0%28.5%$682.6BLLYEli Lilly & Co$65.2B44.7%31.7%$1.3T
MRKMerck & Co., Inc. (this company)$65.0B1.3%28.1%$362.3B
PFEPfizer Inc$62.6B1.6%12.4%$164.3BABBVAbbVie Inc.$61.2B8.6%6.9%$520.5BAZNAstraZeneca PLC$58.7B8.6%17.4%—BMYBristol Myers Squibb Co$48.2B0.2%14.6%$127.4BABTAbbott Laboratories$44.3B5.7%14.7%$185.8BUPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Merck & Co., Inc. · CIK 310158 · Engraved from SEC EDGAR